SLC5A2 and fatty liver disease: As a result, although the use of metformin alone in treating subjects with liver steatosis is not convincingly supported, so far, a number of ongoing trials oriented to the management of the steatotic liver include the use of metformin together with other anti-diabetic drugs as SGLT-2 inhibitors, pioglitazone, liraglutide, gliclazide, sitagliptin [262].